loading...

QUALIVEEN 30 items (QUALIVEEN-30)

Bonniaud V

Distributed by Mapi Research Trust

ProQolid

Distributed by Mapi Research Trust

Basic description

Adapted from the original QUALIVEEN in 2004
A short version, SF-QUALIVEEN, was developed in 2008

Authors

Bonniaud V

Copyright
®QUALIVEEN-30 2008 Dr Véronique Bonniaud, Pr Dianne Bryant, Pr Gordon Guyatt, Pr Bernard Parratte and Coloplast laboratories, All rights reserved.
Objective
To assess health-related quality of life of patients with urinary disorders in neurologic conditions
Therapeutic area
  • Nervous System Diseases
  • Female Urogenital Diseases and Pregnancy Complications
  • Male Urogenital Diseases
Therapeutic indication
  • Generic for Nervous System Diseases
  • Urination Disorders
Urinary disorders in neurologic conditions
Type of Clinical Outcome Assessment (COA)
  • pro PRO
Original language(s)
  • French for France
Bibliographic reference(s) of the original questionnaire

Bonniaud V, Parratte B, Amarenco G, Jackowski D, Didier JP, Guyatt G. Measuring quality of life in multiple sclerosis patients with urinary disorders using the Qualiveen questionnaire. Arch Phys Med Rehabil. 2004 Aug;85(8):1317-23 (PubMed Abstract)

Bonniaud V, Jackowski D, Parratte B, Paulseth R, Grad S, Margetts P, Guyatt G. Quality of life in multiple sclerosis patients with urinary disorders: discriminative validation of the English version of Qualiveen. Qual Life Res. 2005 Mar;14(2):425-31 (PubMed Abstract)

Bonniaud V, Bryant D, Parratte B, Gallien P, Guyatt G. Qualiveen: a urinary disorder-specific instrument for use in clinical trials in multiple sclerosis. Arch Phys Med Rehabil. 2006 Dec;87(12):1661-3 (PubMed Abstract)

Bonniaud V, Bryant D, Parratte B, Guyatt G. Qualiveen, a urinary-disorder specific instrument: 0.5 corresponds to the minimal important difference. J Clin Epidemiol 2008;61(5):505-10 (PubMed Abstract)

Access this questionnaire

Ask Formal Written Permission

Users must receive formal written permission to use the questionnaire before filling out a License Agreement with Mapi Research Trust.

Please contact:

Dr Souad MEILLASSOUX 
Coloplast France  
Phone: (+) 33 1 56 63 17 81
E-mail : frsme@coloplast.com

All requests have to be submitted through our online request management:

  1. Log in or Register for free
  2. Submit your request (Tutorials are available on our FAQs)
  3. Our PROVIDE team will get back to you with the needed information and license agreement in a timely manner.

Fees may apply to your project.


Contact and conditions of use

Authors

Bonniaud V

Unité Pluridsciplinnaire de Pelvi-Périnéologie & Rééducation  
CHU Dijon - Hôpital d'Enfants
14 rue Gaffarel - BP 77 908
21 079 Dijon CEDEX
France

Bonniaud V publications (PubMed)

Contact information

Mapi Research Trust
PROVIDE™
27 rue de la Villette
69003 Lyon
France
Phone: +33 (0)4 72 13 66 66

Conditions of use

Ask Formal Written Permission

Users must receive formal written permission to use the questionnaire before filling out a License Agreement with Mapi Research Trust.

Please contact:

Dr Souad MEILLASSOUX 
Coloplast France  
Phone: (+) 33 1 56 63 17 81
E-mail : frsme@coloplast.com

All requests have to be submitted through our online request management:

  1. Log in or Register for free
  2. Submit your request (Tutorials are available on our FAQs)
  3. Our PROVIDE team will get back to you with the needed information and license agreement in a timely manner.

Fees may apply to your project.

Review copy

Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.

Languages

Original language(s)

  • French for France

Translations

The list of available translations is subject to constant changes and may not be exhaustive. It is provided for information only. Some recently produced translations may not be included in the list below yet. Please do check the status of available translations with Mapi Research Trust / the developers / copyright holders / distributors.

Also, the listed translations may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study.

QUALIVEEN-30

English for Canada
English for the UK
Italian for Italy*
Persian for Iran
* Performed by Mapi

The author has selected Mapi/ICON Language Services as exclusive linguistic validation company to ensure the production of harmonized and consistent language versions.

For additional information on available translations of this instrument, or for a project involving new languages, please submit a request (tutorials available on our FAQs).

Conditions to translate

Academic Translation

If you wish to translate the questionnaire:

  1. Log in or Register for free
  2. Submit your request for translation online (Tutorials are available on our FAQs)
  3. Our PROVIDE team will send you a translation agreement along with Linguistic Validation Guidelines.

Commercial Users

Exclusive vendor for translation work for commercial users: Mapi/ICON Language Services

More information on translations

Bibliographic references of the translations:

English for the UK and Canada:
Bonniaud V, Jackowski D, Parratte B, Paulseth R, Grad S, Margetts P, Guyatt G. Quality of life in multiple sclerosis patients with urinary disorders: discriminative validation of the English version of Qualiveen. Qual Life Res. 2005 Mar;14(2):425-31

Bonniaud V, Parratte B. [Cross-cultural adaptation of health-related quality of life questionnaire: English version of Qualiveen abstract] Ann Readapt Med Phys. 2006 Apr;49(3):92-9. Epub 2006 Feb 2. French 

Bonniaud V, Bryant D, Parratte B, Gallien P, Guyatt G. Qualiveen: a urinary disorder-specific instrument for use in clinical trials in multiple sclerosis. Arch Phys Med Rehabil. 2006 Dec;87(12):1661-3

Bonniaud V, Bryant D, Parratte B, Guyatt G. Qualiveen, a urinary-disorder specific instrument: 0.5 corresponds to the minimal important difference. J Clin Epidemiol 2008;61(5):505-10.

Italian for Italy:
Bonniaud V, Bryant D, Pilati C, Menarini M, Lamartina M, Guyatt G, Del Popolo G. Italian version of Qualiveen-30: cultural adaptation of a neurogenic urinary disorder-specific instrument. Neurourol Urodyn. 2011 Mar;30(3):354-9 (PubMed abstract)

Persian for Iran:
Nikfallah A, Rezaali S, Mohammadi N, Abrishamkar M, Rezaei E, Sahraian MA, Pakpour AH, Yekaninejad MS. Translation, Cultural Adaptation and Validation of the Qualiveen-30 Questionnaire in Persian for Patients with Spinal Cord Injury and Multiple Sclerosis. Low Urin Tract Symptoms. 2015 Jan;7(1):42-9 (PubMed abstract)

Copy of the English for the UK and Canada version: QUALIVEEN-30 in English

  

Copy of the Italian version: QUALIVEEN-30 in Italian

Member Access

Subscribe to PROQOLID to access to full information

Access to advanced descriptions of Clinical Outcome Assessments (COAs)

A question? Contact us